# VALIA & TIMBADIA CHARTERED ACCOUNTANTS

ARVIND P. VALIA
B.COM. (Hons.), F.C.A.
HITEN C. TIMBADIA
B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664 Resi: 2409 5981 / 2409 6420

Fax: 2264 1937

E-mail: valtim09@gmail.com 32, Trinity Chambers, 117, Bora Bazar Street, Fort,

Mumbai – 400 001.

# INDEPENDENT AUDITORS' REPORT

To the Members of SUN PHARMACEUTICALS KOREA LTD.

# Report on Financial Statements

We have audited the accompanying financial statements of SUN PHARMACEUTICALS KOREA LTD. ("the Company"), which comprise the Balance Sheet as at 31st March, 2015 and the Statement of Profit and Loss for the year then ended.

# Management's responsibility for the Financial Statements

The Company's Board of Directors is responsible for the preparation of these financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the Accounting Standards generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate Accounting Policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that are operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

# VALIA & TIMBADIA

CHARTERED ACCOUNTANTS

ARVIND P. VALIA B.COM. (Hons.), F.C.A. HITEN C. TIMBADIA B.COM. L.L.B. (GEN), F.C.A.

Tel: Off: 2269 2624 / 2269 9664 Resi: 2409 5981 / 2409 6420

Fax: 2264 1937

E-mail: valtim09@gmail.com

32, Trinity Chambers, 117, Bora Bazar Street, Fort,

Mumbai – 400 001.

# Opinion

In our opinion and to the best of our information and according to the explanations given to us, the accompanying financial statements give a true and fair view in conformity with the accounting principles generally accepted in India:

- a) in the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2015 and
- b) in the case of the Profit and Loss Account, of the loss for the period ended on that date.

For VALIA & TIMBADIA

**Chartered Accountants** (Firm Regn. No : 112241W)

PLACE: MUMBAI DATED: 25/05/2015

HITEN C. TIMBADIA **Partner** Membership No.038429

### SUN PHARMACEUTICALS KOREA LTD.

BALANCE SHEET AS AT 31ST MARCH 2015			
	Notes	31.03.2015 KRW	31.03.2014 KRW
EQUITY AND LIABILITIES			
Shareholders Funds			
Share Capital Reserve and Surplus	1	100,000,000 (19,022,786)	100,000,000 (18,011,797)
Non Current liability			
Long Term Borrowings (from SPG FZE)		19,910,807	18,901,797
Current liability			
Short term Provisions (Provision for Audit Fees)		222,222	222,222
TOTAL		101,110,243	101,112,222
ASSETS			
Non Current Assets			
<u>Current Assets</u>			
Bank Balance Other Receivable		100,000,000 1,110,243	100,000,000 1,112,222
TOTAL			
		101,110,243	101,112,222
PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2015		31.03.2015	31.03.2014
REVENUE		KRW	KRW
Income			-
Foreign Exchange Gain			845,740
EXPENDITURE			
Expenses Audit Fees Foreign Exchange Loss		222,222 788,766	222,222
Net Gain/ (Loss)		(1,010,989)	623,518
Earnings Per Share		(1)	1
Balance Brought Forward		(18,011,797)	(18,635,315)
Balance Carried Forward to Balance Sheet		(19,022,786)	(18,011,797)

FOR Valia & Timbadia
CHARTERED ACCOUNTANTS

For and on behalf of the Board

HITEN C. TIMBADIASunil GandhiSurendra JoshiPartnerDirectorDirectorPlace:Place:Place:Date:Date:Date:

#### SUN PHARMACEUTICALS KOREA LTD.

Notes forming part of the financial statement for the year ended 31st March, 2015

#### 1. LEGAL STATUS

Sun Pharma Korea Ltd was Incorporated on 20th September, 2011 in Korea and the company number is 110111-4690487

The shareholder and its shareholding in the company is as under:-

	Curre	Current year		Previous year	
Name of the Shareholder	No. of Shares	Share Value	No. of Shares	Share Value	
		KRW		KRW	
Sun Pharma Global FZE	1,000,000	100,000,000	1,000,000	100,000,000	
Total>>	1,000,000	100,000,000	1,000,000	100,000,000	

The Directors of the company is as under:-

Name of the Director Nationality Position

Mr Surendra Joshi Indian Director Mr Sunil Gandhi Indian Director

#### 2. ACTIVITY

The company has not commenced any commercial activity till date.

3 The Financial statements has ben prepared under historical cost convention on an accrual basis and comply with Accounting standards and Accounting principles generally accepted in India

For and on behalf of the Board

Sunil GandhiSurendra JoshiDirectorDirectorPlace:Place:Date:Date :

#### SUN PHARMACEUTICALS KOREA LTD.

#### BOARD OF DIRECTORS' REPORT

The Board of Directors submit its Annual Report together with the audited financial statements for the year ended 31 st March, 2015

#### Operations:

The Company has not commenced any commercial activity till date.

#### Capital:

The authorised, issued and paid-up capital of the Company is 4000000 Ordinary shares of KRW 100 each

#### Directors:

The Directors who served during the year was as follows:

Mr Surendra Joshi (Appointed on September 20, 2011) Mr Sunil Gandhi (Appointed on September 20, 2011)

For and on behalf of the Board

Sunil GandhiSurendra JoshiDirectorDirectorPlace:Place:Date:Date: